

**ILLINOIS STATE  
UNIVERSITY**

**BOARD OF  
TRUSTEES**

**Resolution No. 2020.12/35**  
**COVID-19 Testing Authorization**

**Resolution**

Whereas, the Board of Trustees (the “*Board*”) of Illinois State University (the “*University*”) has the authority to enter into contracts for the provision of goods and services to the University, and

Whereas, the University plans to continue COVID-19 testing of students and offer testing to faculty and staff in the Spring 2021 semester in order to protect the health and well-being of the campus community, and

Whereas, the use of the saliva-based COVID-19 test developed by the University of Illinois - SHIELD that was approved by the Board of Trustees at its October 2020 meeting has not received Emergency Use Authorization from the Federal Drug Administration (FDA) and technology for patient registration, specimen collection, and results notification is still in development by University of Illinois- SHIELD, and

Whereas the University has the need to continue using a third party to process PCR COVID-19 tests and share test results with the University through private and confidential electronic means, and

Whereas, the University contracted with an off-site testing laboratory, Reditus Laboratories, to provide PCR COVID-19 testing on campus in Fall 2020 and has been satisfied with the results, and

Whereas, the current contract with Reditus Laboratories expires December 31, 2020:

Therefore, be it resolved that the Board authorizes the University to enter into a contract to process up to 12,500 PCR COVID-19 tests and share the results with the University through private and confidential electronic means for the period from January 1, 2021 to June 30, 2021 from Reditus Laboratories, at a cost not to exceed \$1.25 million.

Board Action on: _____	Postpone: _____
Motion by: _____	Amend: _____
Second by: _____	Disapprove: _____
Vote:      Yeas: _____ Nays: _____	Approve: _____

ATTEST: Board Action, December 12, 2020

\_\_\_\_\_  
Secretary/Chairperson

**Board of Trustees  
Illinois State University  
COVID-19 Testing Authorization**

COVID-19 cases continue to rise in Illinois and across the country. It is important that the University maintain COVID-19 testing for students to mitigate the spread of COVID-19 on the campus and in the community.

Nearly 25,000 PCR COVID-19 (“PCR”) tests were administered to Illinois State University students and processed by Reditus Laboratories this fall at a cost to date approximating \$2.5 million. The University conducted randomized testing of students living in university housing, students enrolled in courses on campus, and students who work on campus. The two testing sites on campus also accepted student walk-up traffic. Results from on-campus testing were received on average in 3-5 days.

Illinois State University has continued to pursue use of the saliva-based COVID-19 test developed by the University of Illinois - SHIELD. At this time, the Federal Drug Administration (FDA) has not granted the University of Illinois’s request for Emergency Use Authorization. In addition, technology for patient registration, specimen collection, and results notification is still in development by the University of Illinois – SHIELD.

PCR tests are considered the gold standard in COVID-19 testing. PCR tests detect the presence of the virus's genetic material. However, it may take several days to get the results of a PCR test. Whereas, an antigen COVID-19 test detects specific proteins on the surface of the coronavirus. Antigen tests are sometimes referred to as rapid diagnostic tests because test results can be obtained in as little as 15 minutes. While antigen COVID-19 tests are a valuable tool in detecting COVID-19, a negative result cannot definitively rule out an active infection. Thus, a person demonstrating symptoms of COVID-19 or having a high clinical suspicion should also be administered a PCR test. At the start of the 2020 fall semester, antigen tests for COVID-19 were not widely available, and thus not considered for use by the University at that time.

The University has decided to utilize an antigen test for COVID-19 testing to start the semester and until such time as the University of Illinois SHIELD program receives FDA Emergency Use Authorization and technology issues are resolved. The use of the antigen test will allow for notification of results within hours instead of days. This will allow the University to quickly isolate students who test positive and begin contact tracing and identify close contacts to quarantine within hours instead of several days. Antigen tests are also significantly less expensive than the use of the PCR test. However, the University still has a need for a laboratory to process PCR tests for students who are symptomatic, students who test positive with an antigen test but have no symptoms, and student athletes to meet NCAA and conference guidelines for testing.

The University has negotiated with Reditus Laboratories to process PCR COVID-19 tests conducted on campus and to notify Student Health Services of the results through technology that was developed in September 2020.

The University anticipates conducting approximately 625 PCR tests each week for 20 weeks at an estimated cost of \$100 per test. Total PCR tests conducted are expected to not exceed 12,500 in total during the Spring 2021 term.

This resolution seeks authorization to execute a 6-month contract with a cost not to exceed \$1.25 million to process PCR COVID-19 testing conducted on campus and share the results with the University through private and confidential electronic means. The exact number of tests conducted each week will vary based on the prevalence of COVID-19 in the campus population, potential surges on-campus, and number of student athletes tested that week. The University will only pay for tests that are processed.

Should the University of Illinois receive Emergency Authorization Use for the saliva-based test, and if technology issues are resolved, the University may revert to using the saliva-based test on campus for asymptomatic individuals. Student Health Services will continue to test symptomatic students using a PCR test and student athletes will continue to receive weekly PCR tests.

Funding Source: General Revenue Funds, Federal & State Grants as available

**ILLINOIS STATE  
UNIVERSITY**

**BOARD OF  
TRUSTEES**

**Resolution No. 2020.12/36**  
**Authorization for External**  
**Search Firm**

**Resolution**

Whereas, Dr. Larry H. Dietz announced his retirement as President of Illinois State University, and

Whereas, the Board of Trustees of Illinois State University (the “Board”) will immediately begin a search for the next President of Illinois State University and wishes to engage an external search firm to assist the Board with the search, and

Whereas, the Board is authorized to engage an external search firm to assist in the hiring of the President of the University pursuant to Illinois State University policy, and

Whereas, the Board is authorized to use University funds to pay for the services of an external search firm to assist in the hiring of the President of the University pursuant to 110 ILCS 675/20-180:

Therefore, be it resolved that the Board of Trustees of Illinois State University authorizes the engagement of an external search firm to assist the Board of Trustees with the search for the next President of Illinois State University and the use of University funds to pay for the services of the external search firm.

Board Action on: \_\_\_\_\_  
Motion by: \_\_\_\_\_  
Second by: \_\_\_\_\_  
Vote: Yeas: \_\_\_\_\_ Nays: \_\_\_\_\_

Postpone: \_\_\_\_\_  
Amend: \_\_\_\_\_  
Disapprove: \_\_\_\_\_  
Approve: \_\_\_\_\_

ATTEST: Board Action, December 12, 2020

\_\_\_\_\_  
Secretary/Chairperson

**ILLINOIS STATE  
UNIVERSITY**

**BOARD OF  
TRUSTEES**

**Resolution No. 2020.12/37**  
**Approval of Contract Extension**  
**for President Dietz**

**Resolution**

Whereas, the Board of Trustees of Illinois State University (the “Board”) and Dr. Larry H. Dietz (the “President”) entered into a Contract for Services on September 30, 2017, with a term ending June 30, 2020 (the “Contract”), and

Whereas, the Board and the President entered into an amendment to the Contract which extended the term of the Contract to December 31, 2020, and

Whereas, the President announced his retirement as president of Illinois State University effective June 30, 2021, and

Whereas, the Board desires the President to continue as president of Illinois State University, and the President desires to continue as president of Illinois State University until his retirement, and

Whereas, the Board and the President desire to amend the Contract to extend the term of the Contract to June 30, 2021, to authorize the Board to award the President a performance bonus for FY2021 not to exceed \$50,000.00, and to reimburse the President for certain moving expenses upon termination of the Contract:

Therefore, be it resolved that the Board of Trustees of Illinois State University hereby agrees to amend President Dietz’s Contract for Services to extend the term to June 30, 2021, to authorize the Board to award the President a performance bonus for FY2021 not to exceed \$50,000.00, and to reimburse the President for certain moving expenses upon termination of the Contract.

Board Action on: \_\_\_\_\_  
Motion by: \_\_\_\_\_  
Second by: \_\_\_\_\_  
Vote: Yeas: \_\_\_\_\_ Nays: \_\_\_\_\_

Postpone: \_\_\_\_\_  
Amend: \_\_\_\_\_  
Disapprove: \_\_\_\_\_  
Approve: \_\_\_\_\_

ATTEST: Board Action, December 12, 2020

\_\_\_\_\_  
Secretary/Chairperson